A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia


Cappellini M. D., Viprakasit V., Taher A. T., Georgiev P., Kuo K. H. M., Coates T., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.13, pp.1219-1231, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 382 Issue: 13
  • Publication Date: 2020
  • Doi Number: 10.1056/nejmoa1910182
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Page Numbers: pp.1219-1231
  • Istanbul University Affiliated: Yes

Abstract

Background Patients with transfusion-dependent beta-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor beta superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients.